First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Clinical trial NCT05099172 · RECRUITING

Trial details

NCT number: NCT05099172
Sponsor: Bayer
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Non-small Cell Lung Cancer EGFR Mutation HER2 Mutation

Start date: 2021-10-25
Primary completion: 2026-03-16
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.